Xylem Inc. carries a market capitalization of 26.22B, placing it among publicly traded companies globally. Its enterprise value stands at 30.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 26.22B |
| Enterprise Value | 30.57B |
Xylem Inc. currently has 239.10M shares outstanding.
| Shares Outstanding | 239.10M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Xylem Inc. trades at a trailing price-to-earnings ratio of 29.62. The price-to-sales ratio is 3.20, and the price-to-book ratio stands at 7.65.
| PE Ratio | 29.62 |
| PS Ratio | 3.20 |
| PB Ratio | 7.65 |
| P/TBV Ratio | 40.13 |
| P/FCF Ratio | 22.14 |
| P/OCF Ratio | 22.08 |
On an enterprise value basis, Xylem Inc. trades at an EV/EBITDA multiple of 15.93 and an EV/FCF ratio of 22.88. The EV/Sales ratio of 3.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.66 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.36 |
| EV / EBITDA | 15.93 |
| EV / EBIT | 22.66 |
| EV / FCF | 22.88 |
Xylem Inc. maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.35, indicating elevated leverage, while an interest coverage ratio of 76.76 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.46 |
| Quick Ratio | 0.95 |
| Debt / Equity | 18.35 |
| Debt / EBITDA | 1.07 |
| Interest Coverage | 76.76 |
Xylem Inc. posts a return on equity of 27.98 and a return on invested capital of 8.09.
| Return on Equity (ROE) | 27.98 |
| Return on Assets (ROA) | 5.85 |
| Return on Invested Capital (ROIC) | 8.09 |
| Return on Capital Employed (ROCE) | 17.26 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.54 |
Over the trailing twelve months, Xylem Inc. has paid 236.00M in income taxes, reflecting an effective tax rate of 19.54.
| Income Tax | 236.00M |
| Effective Tax Rate | 19.54 |
Xylem Inc.'s stock has declined approximately -13.25993% over the past 52 weeks. The 50-day moving average sits at 117.36, while the 200-day moving average is 133.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | -13.25993% |
| 50-Day Moving Average | 117.36 |
| 200-Day Moving Average | 133.88 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Xylem Inc. generated 9.09B in revenue and converted that into 981.00M in net income, yielding earnings per share of 3.99. EBITDA reached 1.92B, while operating income came in at 1.35B.
| Revenue | 9.09B |
| Gross Profit | 3.51B |
| Operating Income | 1.35B |
| Pretax Income | 1.21B |
| Net Income | 981.00M |
| EBITDA | 1.92B |
| EBIT | 1.35B |
| Earnings Per Share (EPS) | 3.99 |
Xylem Inc. holds 808.00M in cash and equivalents against 2.06B in total debt, resulting in a net debt position of 1.13B. Total book value stands at 3.80B, with working capital of 1.28B providing operational flexibility.
| Cash & Cash Equivalents | 808.00M |
| Total Debt | 2.06B |
| Net Debt | 1.13B |
| Equity (Book Value) | 3.80B |
| Book Value Per Share | 15.62 |
| Working Capital | 1.28B |
Xylem Inc. produced 1.32B in operating cash flow over the past twelve months.
| Operating Cash Flow | 1.32B |
| Capital Expenditures | N/A |
| Free Cash Flow | 1.32B |
| FCF Per Share | 5.41 |
Xylem Inc. operates with a gross margin of 38.61, reflecting its pricing power and cost economics. The operating margin of 14.84 and net profit margin of 10.79 provide insight into operational efficiency.
| Gross Margin | 38.61 |
| Operating Margin | 14.84 |
| Pretax Margin | 13.29 |
| Profit Margin | 10.79 |
| EBITDA Margin | 21.11 |
The company's payout ratio of 41.43 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.64 |
| Dividend Yield | N/A |
| Payout Ratio | 41.43 |
| Shareholder Yield | 3.68 |
| FCF Yield | 4.52 |
Xylem Inc. posts an Altman Z-Score of 6.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.21 |